Foster Wheeler to convert Teesside fish oil facility into API plant

Will use fish oil in omega-3 active pharmaceutical ingredient

Foster Wheeler, an international engineering, construction and project management contractor headquartered in Switzerland, has been awarded a contract by EPAX Pharma UK to convert parts of the former Lundbeck pharmaceutical plant at Seal Sands, Teesside to process fish oil for use in an omega-3 active pharmaceutical ingredient.

A subsidiary of Foster Wheeler’s Global Engineering and Construction Group will carry out the work for the UK subsidiary of Trygg Pharma in Norway, for the provision of engineering, procurement and construction management (EPCm) services.

Financial terms were not disclosed.

Foster Wheeler will provide detailed design, procurement and contracts management on behalf of EPAX, and also project, construction, pre-commissioning and validation management services.

This extends Foster Wheeler’s involvement in the project, which started with basic engineering in the Q3 2011, followed by front-end engineering design. Operational qualification of the converted facility is scheduled for the Q1 2013.

Foster Wheeler was first involved in the Seal Sands facility when, in 2000, it was awarded a contract by Lundbeck to design and build a bulk pharmaceutical facility in 21 months.

Companies